Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
---|
03/20/2008 | US20080070854 Conserved Hbv and Hcv Sequences Useful for Gene Silencing |
03/20/2008 | US20080070853 Peptides Selectively Lethal to Malignant and Transformed Mammalian Cells |
03/20/2008 | US20080070831 Endothelial growth factor; isolated polypeptide; stimulates cell proliferation, neovascularization, vascular system permeability; uses thereof in medical and diagnostic applications |
03/20/2008 | US20080070305 Inhibition of expression of a target gene |
03/20/2008 | US20080070297 Regulatory elements for delivery to the liver |
03/20/2008 | US20080070259 Using presence or absence of mutation in metalloenzyme polynucleotides as diagnostic indicator of cardiovascular and neurodegenerative disorders |
03/20/2008 | US20080070258 Polyamide nucleic acid derivatives and agents, and processes for preparing them |
03/20/2008 | US20080069866 Immunotherapeutic methods and compositions |
03/20/2008 | US20080069840 Immunotherapy ; antigen codes Dna vaccine; antitumor agents |
03/20/2008 | US20080069806 Method of screening for substances useful for transdifferentiation of microglia into neurons |
03/20/2008 | US20080069803 Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions vectors |
03/20/2008 | US20080069802 Glycosylated adenovirus particles; capsids; tumor suppressors; gene therapy |
03/20/2008 | US20080069799 Use of il-22 for the treatment of conditions of metabolic disorders |
03/20/2008 | US20080069798 Hyperlipidemia, obesity, hyperinsulinemia and diabetes; gene therapy |
03/20/2008 | US20080069770 Monoclonal antibodies; used to modulate the immune system; no modulation of the totality of the T-cell population but only of the sub-assembly of T-cells expressing the beta sub-family specific to the T-cell receptors; used for organ transplant rejection |
03/20/2008 | DE10080167B4 Medikament zur Hemmung der Expression eines vorgegebenen Gens Medicament for inhibiting the expression of a given gene |
03/20/2008 | CA2664318A1 Long lasting drug formulations |
03/20/2008 | CA2663045A1 Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells |
03/20/2008 | CA2662560A1 Oligonucleotide non-viral delivery systems |
03/19/2008 | EP1900827A2 Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia |
03/19/2008 | EP1900818A2 Neisserial antigens |
03/19/2008 | EP1900815A2 In vivo production of small interfering RNAs that mediate gene silencing |
03/19/2008 | EP1900813A1 Novel physiological substance nesfatin, substance relevant thereto, and use of the substances |
03/19/2008 | EP1900749A1 Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells |
03/19/2008 | EP1900380A1 Pharmaceutical composition for vascular occlusive disease |
03/19/2008 | EP1900377A1 Inhibitors of GPR87 for cancer therapy |
03/19/2008 | EP1900374A1 Angiogenetic agent containing adrenomedulin as the active ingredient |
03/19/2008 | EP1899487A2 Gfats as modifiers of the axin pathway and methods of use |
03/19/2008 | EP1899470A2 System for rapid production of high-titer and replication-competent adenovirus-free recombinant adenovirus vectors |
03/19/2008 | EP1899466A2 Sirna molecules for treatment of blood vessels |
03/19/2008 | EP1898957A1 Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
03/19/2008 | EP1898956A2 Anti-tumoral compositions and methods |
03/19/2008 | EP1725216A4 Immunoliposome-nucleic acid amplication (ilnaa) assay |
03/19/2008 | EP1513545B1 Methods and means to promote gut absorption |
03/19/2008 | EP1012240B1 Cancer immunotherapy with semi-allogeneic cells |
03/19/2008 | EP0594669B9 Growth factor-responsive neural progenitor cells which can be proliferated in vitro. |
03/19/2008 | CN101146827A HIV TAT-CD4 hybried molecules and methods of use thereof |
03/19/2008 | CN101146547A Use of myostatin (GDF-8) antagonists for improving wound healing and preventif fibrotic disease |
03/19/2008 | CN101146546A Muscle regeneration |
03/19/2008 | CN101144081A Nucleic acid molecule TRAIL and application in preparation of anti-tumour pharmaceutical |
03/19/2008 | CN101143895A Polypeptide with tumour targeting effects and preparation method thereof |
03/19/2008 | CN101143222A Application of p53 expression product in preparing medicine for treating tumor |
03/19/2008 | CN101143221A Central airway administration for systemic delivery of therapeutics |
03/19/2008 | CN100375785C Clone, expression and anti-tick immanoprotection action of falcate rhipicephalus RhcA and RhcB genes |
03/18/2008 | US7345138 Biodegradable polyphosphates for controlled release of bioactive substances |
03/18/2008 | US7345026 A part of the coding sequence of the middle glycoprotein of the hepatitis B virus, which has a dna sequence coding for at least one tumor epitope of a tumor antigen inserted |
03/18/2008 | US7345025 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
03/18/2008 | US7344883 Human embryonic kidney cells and amniocytes; capable of complementing recombinanat adenovirus |
03/18/2008 | US7344872 involves engineering a recombinant shuttle vector comprising a nucleic acid cassette encoding prokaryotic green fluorescent protein (GFP) operably linked to regulatory sequences which permit its expression in a host cell |
03/18/2008 | US7344844 Can be used for the treatment of diabetes or for delaying the onset of diabetes |
03/18/2008 | US7344833 Methods and compositions for modulating activator protein 1 |
03/18/2008 | US7344715 Method for treating multiple myeloma |
03/18/2008 | US7344711 Administering an adenovirus defective in its VAI and VAII virus-associated RNAs |
03/18/2008 | US7344710 Aministering synergistic mixture of Clostridium spores and anticancer agents |
03/18/2008 | CA2448908C Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization |
03/18/2008 | CA2320430C Recombinant mistletoe lectins |
03/18/2008 | CA2266781C Piperazine based cytofectins |
03/18/2008 | CA2181073C Tissue-specific enhancer active in prostate |
03/18/2008 | CA2166102C Redirection of cellular immunity by receptor chimeras |
03/14/2008 | CA2568354A1 Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof |
03/13/2008 | WO2008030557A2 Compositions and methods for enhancing transport through mucus |
03/13/2008 | WO2008029871A1 Nerve fiber degeneration inhibitor |
03/13/2008 | WO2008029868A1 Ocular fibrous neovascularization inhibitor |
03/13/2008 | WO2008029790A1 Novel nucleic acid |
03/13/2008 | WO2008029619A1 Ena antisense oligonucleotide having sequence-specific action |
03/13/2008 | WO2007134460A8 Pancreatic b-cells expressing abca1 and uses thereof |
03/13/2008 | WO2007129114A3 Aptamers directed to recombinant muc1 |
03/13/2008 | WO2007100568A3 T cell receptors and related materials and methods of use |
03/13/2008 | WO2007048628A3 Structures of active guide rna molecules and method of selection |
03/13/2008 | US20080064651 A 21-base antisense oligonucleotide which inhibits gene expression of testosterone-repressed prostate message-2 by tumor cells; prostate and renal cell cancer; enhanced chemosensitivity, hormone and radiation sensitivities |
03/13/2008 | US20080064649 Anticarcinogenic and antiproliferative agents in combination with radiation therapy, chemotherapy, ablative surgery, or partially ablative surgery for bone and breast cancer treatments |
03/13/2008 | US20080064106 Lentiviral LTR-deleted vector |
03/13/2008 | US20080064081 Reducing antigenicity of viral protein via amino acid sequence variation; enhancing vector transferability during gene therapy |
03/13/2008 | US20080063898 Materials containing multiple layers of vesicles |
03/13/2008 | US20080063701 Lipids of a liposome comprising cationic N1-cholesteryloxycarbonyl-3,7-diazanononane-1,9-diamine and/or noncationic dioleoyl phosphatidylethanolamine and short interference RNA (siRNA) are coupled, reversibly or irreversibly, to one or more polymers; drug delivery; freeze drying |
03/13/2008 | US20080063696 Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant |
03/13/2008 | US20080063661 treating a wart with a fusion protein comprising (1) a heat shock protein and (2) a human papilloma virus (HPV) protein; Mycobacterium bovis heat shock protein; HPV is an E7 protein; cervical dysplasia, anal cancer, anal dysplasia |
03/13/2008 | US20080063655 nucleic acid sequences encoding a 30 kD Brachyspira hyodysenteriae lipoprotein; host cell; new locus comprising four genes has now surprisingly been found; swine dysentery |
03/13/2008 | US20080063643 HLA-binding motif in its sequence; recognized by an HLA-A2- or HLA-A24-restricted cytotoxic T cell; nucleotide; antibody; vector; diagnosid and prognosis of hepatitis C virus infection |
03/13/2008 | US20080063629 culturing progenitor or stem cells with stromal cells in cytokines; genetic engineering |
03/13/2008 | US20080063626 Minimization of drug oxidation in drug irradiated excipients formulations |
03/13/2008 | DE112004002217T5 Proteinbildungskomplex mit einem c-Jun-Protein, Nucleinsäure, codierend denselben und Verfahren unter Verwendung desselben The same protein complex formation with a c-Jun protein, nucleic acid encoding the same and methods using |
03/13/2008 | CA2663109A1 Hsv-1 and hsv-2 vaccines and methods of use thereof |
03/13/2008 | CA2663003A1 Compositions and methods for enhancing transport through mucus |
03/12/2008 | EP1897948A1 Mammalian transforming growth factor beta 9 |
03/12/2008 | EP1897942A1 Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
03/12/2008 | EP1897553A1 Inhibitor of stem cell proliferation and uses thereof |
03/12/2008 | EP1897540A2 Inhibition of STAT3 signal transduction for human cancer therapy |
03/12/2008 | EP1897441A1 TGF-alpha polypeptides, functional fragments and methods of use therefor |
03/12/2008 | EP1896587A2 METHODS FOR PRODUCING MICRORNAs |
03/12/2008 | EP1896083A2 A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
03/12/2008 | EP1506317B1 Marker molecules associated with lung tumors |
03/12/2008 | EP1450751B1 Nanoparticle delivery vehicle |
03/12/2008 | EP1444346B1 Sirna knockout assay method and constructs |
03/12/2008 | EP1278855B1 Compounds and methods for treatment and diagnosis of chlamydial infection |
03/12/2008 | EP1045702B1 Methods of controlling cell differentiation and growth using a fusion protein and a drug |
03/12/2008 | EP0973538B1 Modified proteins which bind extracellular matrix components |
03/12/2008 | EP0614374B2 MURINE MONOCLONAL ANTIBODY (5c8) RECOGNIZES A HUMAN GLYCOPROTEIN ON THE SURFACE OF T-LYMPHOCYTES |
03/12/2008 | CN101142614A Single channel image deformation system and method using anisotropic filtering |
03/12/2008 | CN101141982A Method and pharmaceutical composition for treating psoriasis, squamous cell carcinoma and/or parakeratosis by inhibiting expression of squamous cell carcinoma-related antigen |